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Summary In a previous study, urologists, radiation oncologists and medical oncologists in Britain, Canada
and the United States were asked to state how they would wish to be treated if they had urologic cancer as
described in six clinical scenarios and whether they would agree to be entered in randomised clinical trials.
This study disclosed major controversy regarding treatment options for each scenario and reluctance by these
experts to enter randomised clinical trials. In the present study a second questionnaire which included a
summary of the treatments selected initially was sent to the same 227 oncologists. Respondents were asked, in
view of these additional information, how they would wish to be treated and whether they would enter
themselves (or their patients) on randomised trials comparing the two treatment options most favoured by
their colleagues. Most respondents did not modify their treatment preference. There was still poor agreement
to enter themselves on trials (29%), but a higher proportion would offer such trials to their patients (45%).
Thus the demonstration of controversy about optimum treatment did not influence personal bias, but could
facilitate the entry of patients into trials that address major controversies. We conclude that treatment
strategies of urologic oncologists are influenced minimally by opinions of their colleagues, but that the method
of using surrogate questionnaires is a valuable aid to the design of clinical trials.
There is a large degree of controversy about the optimal
management of patients with genitourinary malignancies.
Despite this lack of consensus there has been only a small
number of randomised clinical trials in urologic oncology
that have addressed controversies regarding optimal treat-
ment strategies (Raghaven et al., 1989).
In an attempt to define controversies in the management of
GU malignancies, and to establish whether current clinical
trials in urologic oncology address important questions, we
have surveyed previously 227 urologists, radiation oncolo-
gists and medical oncologists in Canada, Great Britain and
the United States (Moore et al., 1988). The population
surveyed included one group of community based urologists,
and the remainder were specialists known to practice urologic
oncology on the basis of a publication about prostate or
bladder cancer within the previous 3 years. The survey used
the physician surrogate method initially developed for a
study examining treatment preferences of physicians for dif-
ferent presentations of non-small cell lung cancer (Mackillop
et al., 1986, 1987). Six clinical scenarios in bladder, prostate
and kidney cancer were presented. For each scenario the
doctor was asked which treatment he would select for himself
if he were the patient. In association with each scenario were
one or two currently ongoing randomised clinical trials for
which these physician surrogates would be eligible. The doc-
tors were asked if they would agree to be randomised on
such a trial, and if they refused, to give their reasons.
The survey revealed that there was substantial disagree-
ment amongst these experts as to the treatments they would
select when dealing with superficial bladder cancer, locally
advanced bladder cancer, metastatic bladder cancer, localised
prostate cancer, metastatic prostate cancer and metastatic
kidney cancer. Treatments selected were influenced predom-
inantly by the speciality and country of practice of the
respondents. The central findings were a preference by
specialists to select their own treatment modality and a
preference by British urologists to choose more conservative
treatment approaches than their North American colleagues.
Despite the lack of consensus about treatment decisions,
agreement to enter randomised clinical trials that addressed
major controversies was poor. The results of the survey
suggested that the specialists had strongly held beliefs in the
absence of clear data in the literature to support their biases.
In the present study we have determined the impact of the
results of our previous questionnaire on these specialists. We
have summarised the original responses which demonstrate
the great diversity of opinion amongst experts and question-
ed whether this would lead them to change their management
decisions. We have also asked the clinicians whether it would
influence their agreement to enter themselves or their patients
into clinical trials that address current treatment controver-
sies. Finally, we sought to evaluate this methodology for its
use in the assessment of ongoing or proposed clinical trials;
specifically to assess whether trials ask relevant questions, are
feasible and should be offered to patients on ethical grounds.
Materials and methods
A questionnaire was mailed to the same 227 expert clinicians
who received our initial survey. The questionnaire contained
three clinical scenarios concerning locally advanced bladder
cancer, localised prostate cancer and metastatic kidney
cancer. These scenarios were identical to three of those in the
initial questionnaire and asked the doctor to imagine that he
had a certain type and stage of G-U cancer. For each
scenario the specialists were given a summary of the treat-
ment selections of the 157 respondents to the intial question-
naire and a breakdown of responses on the basis of speciality
and location. The doctors were then asked which treatment
they would select for themselves and whether they would
agree to be randomised on the same clinical trials as present-
ed in the initial questionnaire. In addition, for each scenario,
they were asked if they would agree to be randomised on a
hypothetical trial that compared the two treatment options
most commonly chosen by respondents. The doctors were
also asked if they would enter patients in their practice on
these trials. Demographic data on speciality, location, age,
type of practice and experience in urologic oncology was
obtained. Those surveyed were also asked to give their
opinion on the utility of this type of questionnaire in defining
current treatment controversies and in evaluating the
relevance, feasibility and ethics of clinical trials.
Results
Retirement, change of location or death decreased the
number of doctors surveyed from 227 initially to 217 in the
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follow-up. Of those surveyed 157 have replied (72.3%). Re-
sponse from British and US clinicians was notably better
than that from Canadians.
Localisedprostate cancer
The scenario was: 'You are 67 years old and have noted
decreasing stream and increasing frequency and nocturia dur-
ing the last 6 months. You consult a urologist who discovers
a firm 1.5 cm nodule confined to the right lobe of your
prostate. Needle biopsy shows moderately differentiated
adenocarcinoma with a Gleason biopsy score of 5. Your acid
phosphatase, bone scane, chest X-ray, lymphangiogram and
CT scan of abdomen and pelvis are all normal. How would
you wish to be treated?'
The responses to the previous questionnaire were then
summarised (presented in parenthesis in Table I).
As shown in Table I, most of the treatments selected were
similar to those chosen in the initial survey. The only change
was an increase in preference for radiation therapy by British
urologists and US medical oncologists. Over 95% of the
physicians were aware that controversy existed about the
management of localised prostatic cancer.
In the initial survey 31% of doctors stated they would
agree to be randomised in a trial comparing radical prosta-
tectomy to radiation therapy. After reviewing the evidence
demonstrating the degree of controversy among their col-
leagues 29% stated they would agree to be randomised in
such a trial. However, 58% of respondents stated that they
would approach a patient in their practice about entry into
this trial (P<10-1).
Locally advanced bladder cancer
The scenario was: 'You are 58 years old and have been
investigated following a 2-month history of intermittent pel-
vic pain and a 1-week history of haematuria. Your urologist
informs you that cystoscopy showed a 6 cm broad-based
tumour involving the right hemi-trigone and ureteral orifice,
and that after biopsy of the lesion he could feel a 5 cm
mobile mass under anaesthesia. Pathology has shown poorly
differentiated transitional cell carcinoma with invasion of
deep muscle. Your IVP has shown dilatation of the right
ureter and a filling defect in the bladder. Chest X-ray, bone
scan, lymphangiogram and liver function tests are normal.
Your CT scan of the abdomen and pelvis shows the mass in
the bladder wall but no enlarged lymph nodes. How would
you wish to be treated?'
The responses to the previous questionnaire were then
summarised (presented in parenthesis in Table II).
We did detect changes in treatment preferences in the
follow up questionnaire (Table II). This related to the use of
chemotherapy either by itself or in combination with cystec-
tomy and/or radiotherapy. Initially 28% of physicians select-
ed chemotherapy as part of their treatment while in the
follow-up study this had increased to 43% (P<0.008).
Medical oncologists were particularly in favour of this ap-
proach with 79% choosing to include chemotherapy as part
of their treatment. This tendency to use chemotherapy was
observed mainly for respondents in the United States with
chemotherapy selected by less than 20% of specialists from
Canada and Great Britain. The tendency for clinicians to
favour treatment with their own treatment modality and the
preference of British physicians for more conservative treat-
ment persisted in the follow-up sudy. Only 6% of respon-
dents were unaware that controversy about the management
of locally advanced bladder cancer existed amongst their
colleagues.
The respondents were asked to consider randomisation in
a trial comparing radiotherapy alone to radiotherapy fol-
lowed by cystectomy. Only 16% agreed as compared to 18%
in the initial questionnaire. However, 32% stated they would
offer randomisation in this trial to one of their patients.
Respondents were also asked whether they would agree to be
randomised into a trial comparing the two treatment
approaches most frequently chosen in the initial survey
(radical cystectomy vs radical cystectomy + radiation ther-
apy). Thirty-two per cent would agree to be randomised in
this trial while 41% would offer randomisation in such a trial
to one of their patients. As might be expected 50% of
physicians who chose either radical cystectomy or cystec-
tomy+ radiation therapy agreed to randomisation in this
trial while 15% of physicians who chose other approaches
agreed to be randomised. The predominant reason that these
trials were unacceptable to clinicians was a requirement that
any trial in this disease should include an arm that used
chemotherapy.
Metastatic renal cell carcinoma
The scenario was: 'You are 48 years old and undergo a
routine physical examination and chest X-ray for insurance
purposes. Your physical examination is normal but the chest
X-ray shows two 2 cm nodules in the left lower lobe and a
3 cm nodule in the right lower lobe. You undergo needle
biopsy which shows clear cell adenocarcinoma consistent
with a renal primary. CT scan of your abdomen shows a
6 cm mass in the upper pole of the right kidney with no
evidence of perinephric or hilar extension. No other evidence
of metastatic disease is found. How would you wish to be
treated?'
The responses to the previous questionnaire were then
summarised (see in parentheses in Table III).
Treatment selections changed marginally and preferences
were distributed evenly among the four most popular options
(Table III). The proportion of specialists choosing no treat-
ment was equal among physicians of different locations and
specialities.
Respondents were then asked if they would agree to be
randomised on a trial comparing human lymphoblastoid
interferon alone to interferon plus vinblastine. Originally
48% had agreed to enter this trial. In the follow-up 53% of
physicians agreed to be randomised and 60% stated they
would enter their patients on such a trial. Among the 157
specialists who responded to our questionnaire none chose
treatment with interferon or vinblastine for themselves.
The respondents were then asked if they would agree to be
randomised in a hypothetical trial that compared the two
options chosen most frequently by these experts in the
original survey - nephrectomy (chosen by 29%) vs no treat-
ment (chosen by 24%). Only 24% of physicians agreed to be
randomised in such a trial while 37% stated they would offer
this trial to their patients. Among doctors who had chosen
either nephrectomy or no treatment for themselves agreement
was 33%.
Table I Summary of responses to follow-up questionnaire for the scenario related to localised prostate
cancer (responses to original questionnaire are shown in parentheses)
All Urologistsin Medical Radiation
Selected respondents Britain Canada USA oncologists oncologists
management % % % % % %
Prostatectomy 39 (40) 12 (4) 71 (61) 68 (79) 37 (42) 0 (8)
Radiotherapy 51 (39) 60 (44) 21 (13) 12 (8) 59 (46) 100 (92)
Transurethral resection 5 (9) 24 (44) 0 (3) 8 (4) 0 (0) 0 (0)
only
Other 5 (12) 4 (7) 8 (24) 12 (8) 4 (12) 0 (0)990 M.J. MOORE et al.
Table II Summary of responses by speciality and location for the scenario related to locally advanced
bladder cancer (responses to original questionnaire are shown in parentheses)
All Urologists in Medical Radiation
Selected respondents Britain Canada USA oncologists oncologists
management % % % % % %
Radical cystectomy 22 (32) 8 (11) 44 (53) 40 (60) 14 (29) 6 (4)
Cystectomy and 22 (22) 24 (15) 31 (32) 4 (8) 7 (18) 44 (39)
radiotherapy
Cystectomy and 22 (12) 12 (4) 14 (5) 36 (20) 61 (25) 0 (8)
chemotherapy
Chemotherapy and 13 (5) 0 (4) 5 (0) 4 (0) 7 (7) 38 (12)
radiotherapy
Radiotherapy 10 (14) 44 (44) 0 (0) 0 (0) 0 (0) 9 (31)
Other 11 (15) 12 (22) 6 (10) 16 (12) 11 (21) 3 (6)
Treatment includes 43 (28) 16 (22) 22 (11) 56 (32) 79 (50) 38 (23)
chemotherapy
Table III Treatment preferences for scenario related to mestatic renal
cell cancer (responses to original questionnaire in parentheses)
Follow-up Original
% (%)
No treatment 26 (24)
Nephrectomy and metastatectomy 23 (20)
Nephrectomy and systemic therapy 22 (15)
Nephrectomy only 21 (29)
Other 8 (12)
Assessment ofthe methodology
At the conclusion of the questionnaire respondents were
asked to evaluate this type of survey for its clinical utility.
There was general agreement that this method of evaluation
of treatment preferences of experts did provide clinically
useful information. This was seen both in terms of its use by
defining treatment controversy and in the evaluation of the
feasibility, relevance and ethical validity of clinical trials
(Table IV).
Discussion
In our original study we demonstrated significant differences
in treatment preferences amongst doctors of different special-
ities and countries. Most notably this represented a bias by
specialists to use their own treatment modality whenever this
was feasible. In addition we noted that urologists from Great
Britain had a more 'conservative' treatment approach than
their North American counterparts. British urologists select-
ed no treatment in preference to chemotherapy when dealing
with locally recurrent superficial bladder cancer and meta-
static bladder cancer, and selected radiation therapy in
preference to radical surgery when dealing with locally
advanced bladder cancer and localised prostate cancer. While
no clear consensus emerged about the treatment ofany ofthe
six clinical problems we presented, there was sparse agree-
ment by these physicians to be randomised into clinical trials
that sought to resolve some of the controversies.
Our follow-up questionnaire sought to disclose some
potential reasons for the poor support of these clinical trials.
Possibilities might include (i) a lack of awareness that alter-
native forms of management were considered acceptable by
colleagues, (ii) a wish to select one's own treatment on the
Table IV Respondents opinion of the physician surrogate
methodology
Is the method useful to Yes No (%)
Help define current treatment controversies? 135 22 (86)
Evaluate whether clinical trials address relevant 123 33 (79)
questions?
Evaluate the feasibility ofclinical trials? 130 25 (84)
Evaluate ifclinical trials could ethically be 118 37 (76)
offered to patients?
basis of one's own bias, (iii) individual bias confounded by
failure to recognise that beliefs were not based on objective
information, or (iv) the opinion that current clinical trials
were not addressing clinically relevant questions.
Our study has shown that there is general recognition of
controversy among the urologic oncology community about
the management of many common clinical problems. Ninety-
five per cent of the respondents stated that they were aware
of such controversy. Recent meetings such as the NCI con-
sensus development conference have served to highlight these
disagreements (National Institutes of Health, 1988). There-
fore, one cannot attribute poor physician support of trials to
an ignorance of controversy.
The present survey demonstrated consistently a higher rate
of agreement by physicians to enter their patients rather than
themselves into randomised clinical trials (P< 10-6). Some
respondents questioned the ethics of a doctor who would not
agree to be randomised into a clinical trial that he would
offer to one of his patients. We would agree with this state-
ment in the context of a trial that included a treatment
approach that was unconventional, dangerous or previously
shown to be of no benefit. In their previous study of
physicians treating lung cancer Mackillop et al. (1986) iden-
tified such situations. The trials presented in our question-
naire did not offer unconventional options. For example, the
proposed trial comparing radical prostatectomy with radia-
tion therapy for localised prostate cancer compares two
treatments which are equally accepted amongst the expert
community. Freedman (1987) has defined this state of
genuine uncertainty amongst experts about the relative merits
of treatments as 'equipoise'. It would appear reasonable for a
physician to have an individual preference for one of these
options. It also seems quite defensible that a physician might
wish to follow his individual bias when selecting treatment
for himself but to recognise that equipoise exists and to offer
alternative strategies to his patients.
While specialists recognise that controversy exists they
appear to have difficulty in accepting that their own opinions
may not be based on scientific data. Many comments on the
questionnaires supported this premise ('prostatectomy offers
the best chance of cure', 'prostatectomy too toxic'. 'toxicity
of radiation too great' etc.). This could reflect problems
inherent in having modality oriented methods of training and
practice when dealing with diseases whose optimal manage-
ment may be multidisciplinary. Physicians-in-training and
specialists may lack exposure to alternative points of view.
Psychological research demonstrates that we tend to conform
with the beliefs of our colleagues. In addition we more
readily believe and recall information that supports our
biases while disregarding evidence that conflicts with them
(Aronson, 1972).
It is remarkable that there was such good agreement (53%)
by clinicians to be randomised into the trial of interferon
with or without vinblastine if they had asymptomatic meta-
static renal cell cancer. This occurred despite the fact that no
physician chose either of these agents as their preferred treat-TREATMENT STRATEGIES OF ONCOLOGISTS 991
ment. In contrast, the trial comparing radical prostatectomy
with radiation therapy for localised prostate cancer involved
the two treatment options selected by 90% of respondents
but only 29% agreed to participate. These findings suggest
that some trials which are successful in accruing patients may
be lacking in clinical relevance. This situation may have
developed from an awareness that clinical trials which ad-
dress controversial issues are difficult to carry out. Clinical
relevance is then sacrificed for the sake of feasibility in a
setting where clinical investigation is seen as a desirable
activity. A clinical trial that seeks to answer a clinically
irrelevant question, even if of exquisite methodology, is at
best a waste of resources that could be employed elsewhere.
Presentation to the specialists of the treatment preferences
of their colleagues did not appear to change their decisions
about treatment. There was, however, a marked increase in
the number of physicians who chose treatment that included
chemotherapy for locally advanced bladder cancer. There
was an 18 month interval between the two questionnaires.
Chemotherapy is being used increasingly in this clinical set-
ting but we are not aware of any definitive evidence to
support the use of chemotherapy for locally advanced blad-
der cancer that has been published between the times of the
two questionnaires. While the use of chemotherapy may be
logical in a disease with a poor prognosis and a high rate of
metastatic failure, it remains experimental therapy. Many
respondents may have preferred to be treated with experi-
mental therapy, rather than with an established standard
treatment that is known to offer a low probability of cure.
The high rate of return seen in both our original and
follow-up surveys indicates that physicians are supportive of
such endeavours and that the information obtained is
representative of the opinions of the expert community. It
also suggests that this method could be applied more
generally as an aid in clinical investigation. We believe that
surveys such as ours provide information useful for both
patient management and clinical trials. They can define cur-
rent treatment policies and controversies and can frame
meaningful questions which could be addressed in clinical
trials. Knowledge about the acceptability of clinical trials to
expert physicians furnishes useful information as to whether
these trials address relevant issues, can identify potential
problems in their execution and can identify trials that offer
unconventional treatment. We also believe that this method
can strengthen the ethical validity of a proposed trial.
Patients traditionally rely on their individual physician for
guidance as to whether they should consent to be randomised
in a trial, and it has been demonstrated that the opinions of
expert physicians influence the decisions of lay people to take
part in clinical trials (Mackillop et al., 1989). The demonstra-
tion that a clinical trial seeks to answer a question about
which controversy exists among experts, and that all pro-
posed treatment options are acceptable within the expert
community, is information that both patients and institu-
tional review boards would find pertinent.
The stimulation to do these investigations provided by the work of
Dr William Mackillop is gratefully acknowledge. We would also like
to thank the many urologic oncologists who took the time to com-
plete these two questionnaires.
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